APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis - Wikidata - awgldk - TriplyDB

APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis

APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis

http://www.wikidata.org/entity/Q36907709

about

Cytokines and MicroRNAs as Candidate Biomarkers for Systemic Lupus Erythematosus Profile of atacicept and its potential in the treatment of systemic lupus erythematosus The pathogenesis, diagnosis and treatment of lupus nephritis.Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy.Biomarker profiling for lupus nephritis.Dialogue: A blissful future for lupus nephritis: harnessing repeat kidney biopsies to identify meaningful biomarkers of disease.Biomarkers for kidney involvement in pediatric lupus.Surface APRIL Is Elevated on Myeloid Cells and Is Associated with Disease Activity in Patients with Rheumatoid Arthritis Association Study of a Proliferation-inducing Ligand, Spermatogenesis Associated 8, Platelet-derived Growth Factor Receptor-alpha, and POLB Polymorphisms with Systemic Lupus Erythematosus in Chinese Han Population.Sustained remission in lupus nephritis: still a hard road ahead.Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases.To target or not to target APRIL in systemic lupus erythematosus: that is the question!Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus.TACI-dependent APRIL signaling maintains autoreactive B cells in a mouse model of systemic lupus erythematosus.Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): potential biomarkers of active lupus nephritis.Insulin-like growth factor binding protein-2 as a novel biomarker for disease activity and renal pathology changes in lupus nephritis.Novel biomarkers for systemic lupus erythematosus.

P2860

Q26782454-BFAE983F-F233-44AC-8FC1-D8559579B880 Q26849719-63BAFEF1-8D58-4F6B-9C60-2383AB2A665B Q30596968-BA7153F0-7466-48AC-B18F-247005A89ED5 Q35008162-F029C398-3DE1-44F9-9C02-942AAF1F808F Q35171894-A8ACD211-47DE-4EF0-A672-C6D2B17FD952 Q35280905-75F0188C-F671-4045-B11B-63FF48185F9E Q35810911-E82A3AD9-B00A-44A2-8118-62B51FABC094 Q35864231-F846DC59-7E77-4384-9B5B-12EE6B91E56A Q37228509-6B94183C-9240-489D-9C6A-529C23EACDBF Q38641358-59CF6154-2BF6-4B49-97E9-3BE97A72B9A8 Q38755707-CCFF939F-F8C7-41B0-9186-C7CEB48A9DB7 Q43140608-8A9FD938-E921-4910-BD13-CDBD0AFFA94C Q50705075-F892A12B-6302-4168-8982-29AF9C4B6C8F Q51108455-E50F1B61-714E-4175-9067-EC590C985CD0 Q51349898-8077326A-D9A6-4FB8-A303-AB834C361E0C Q51625758-0EA1F8FD-5E70-43F8-B960-DD9371FBFE95 Q52552445-084E4BDD-65C4-4876-B316-F3BCB0719524

P2860

APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis

http://www.wikidata.org/entity/Q36907709

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis

@en

type

label

APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis

@en

prefLabel

APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis

@en

P1433

Q36907709-4AA185AE-D6EE-49AA-9D26-A9B14C268285

P1476

Q36907709-4E65C8F1-0938-43E4-86BD-8E446ACB8BFD

P2093

Q36907709-2B5027A9-7434-4E00-8405-7E5F87A0D5A9

Q36907709-3E7EB1D9-0919-4475-87C9-0F5A10B8420E

Q36907709-516F7CCA-846D-427F-8FC7-1F1077139BE4

Q36907709-602234D9-426C-4439-B2D4-146DEAA5AADC

Q36907709-77DCB263-FD66-492D-80D7-5F35A77E9DCC

Q36907709-B3DED377-25D4-440A-A951-9CC134594EF2

Q36907709-E27145B2-B87F-4A6D-873E-DB66987B5834

Q36907709-F3BBD109-7DC1-4F20-A5C8-4569C71A50F2

Q36907709-F4D2F104-19D1-4556-B545-D0715BDA7B17

P2860

Q36907709-0543A473-9719-4FEF-8B6A-F3812EA8741A

Q36907709-0656A750-168D-4A28-A20A-E6C7327B3C6B

Q36907709-0DB61735-C1D4-43B2-B429-7CA5D8C90294

Q36907709-1358C5C6-8F1D-4F47-BA7E-B15D7197A4AB

Q36907709-151F72B8-2D4A-42DA-B759-603C1791A42B

Q36907709-1DD051D3-1725-4679-A435-CC92AE9D90D7

Q36907709-21BB615A-12D9-4DE6-B0E1-833CB58D8CE6

Q36907709-23C12317-A7D2-43B8-A010-453255B81D47

Q36907709-38FD7AA2-8388-493C-91AA-86C0D1456758

Q36907709-3DF769BE-6DC6-4B41-BD6E-42D3BCC0CA57

P2888

Q36907709-82393988-7DFE-4FCC-96BE-264F87ACE823

P304

Q36907709-35F29798-AD34-47EF-B388-C1F240A9996A

P31

Q36907709-100DEFAA-35CA-4F8F-A8AA-DEF1F614F57C

P356

Q36907709-5DA162EE-C994-46EB-8969-2A9E5B2A8BC2

P433

Q36907709-4351410E-A5D9-46BD-A3A4-90C3F6C8E86C

P478

Q36907709-C53AA99A-63A8-4DD5-9984-DEAE7E13D02E

P577

Q36907709-E2AD70E1-22A1-4C27-9278-43EC9D8A0CE5

P5875

Q36907709-C0A50C8F-2AFC-4FA7-BB3B-F62264A263FF

P6179

Q36907709-1EB96581-216D-4168-B930-7BB812785C50

P698

Q36907709-1BAFD27A-4575-416C-8AD6-90920841A323

P932

Q36907709-FAF830F6-B5FE-4B1C-BEDC-2A0CCE84930B

P356

P1433

Arthritis Research and Therapy

P1476

APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis

@en

P2093

Asada Leelahavanichkul

http://www.w3.org/2001/XMLSchema#string

Nattiya Hirankarn

http://www.w3.org/2001/XMLSchema#string

Poorichaya Somparn

http://www.w3.org/2001/XMLSchema#string

Pornpen Tantivitayakul

http://www.w3.org/2001/XMLSchema#string

Somchai Eiam-ong

http://www.w3.org/2001/XMLSchema#string

Thitima Benjachat

http://www.w3.org/2001/XMLSchema#string

Wipawee Kittikowit

http://www.w3.org/2001/XMLSchema#string

Worapot Treamtrakanpon

http://www.w3.org/2001/XMLSchema#string

Yingyos Avihingsanon

http://www.w3.org/2001/XMLSchema#string

P2860

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

B cell depletion may lead to normalization of anti-platelet, anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosus.

B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data.

BLyS and APRIL in rheumatoid arthritis.

Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome

Intrarenal production of B-cell survival factors in human lupus nephritis.

The classification of glomerulonephritis in systemic lupus erythematosus revisited.

P2888

P304

R252

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/AR4095

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233745014

http://www.w3.org/2001/XMLSchema#string

P6179

1003428091

http://www.w3.org/2001/XMLSchema#string

P698

23171638

http://www.w3.org/2001/XMLSchema#string

P932

3674621

http://www.w3.org/2001/XMLSchema#string